Single point of failure in batch release.

An owner-led, mid-sized CDMO focused on aseptic filling lost its Head of Quality Management to a competitor at short notice. The timing could hardly have been worse. Several customer audits were running in parallel while a demanding tech transfer was due. In a market segment where sterile fill-finish capacity is structurally scarce and outsourcing to contract manufacturers is the fastest-growing area of demand, this is precisely the moment when a CDMO has to prove its reliability to its clients.

The real edge of the situation, however, was not in the open audit but in the statics of responsibility. Batch release rested on the single remaining Qualified Person. Under § 19 of the German Medicines Act (AMG), it is exclusively the Qualified Person who certifies every batch before it is placed on the market. Without personnel redundancy, this legally mandatory function became a classic single point of failure, and that under the tightened inspection standard of the fully revised EU GMP Annex 1 in force since 25 August 2023. For us as a specialised pharma recruitment firm it was clear that this was not about backfilling a role, but about closing a regulatory availability gap.

A failed placement would have triggered several risks at once. As long as batch release hangs on a single person, one absence is enough to block certification and thereby the release of entire batches. For a contract manufacturer this means immediate delivery delays towards the client and potential contractual penalties.

Heavier still was the audit context. Clients assess their CDMO partners rigorously by regulatory track record. Critical findings in the live customer audits would have endangered the approved-supplier status, and a client pulling volume is existence-threatening for a mid-sized CDMO. On top of that came inspection exposure under Annex 1, where documented gaps in contamination control can trigger batch holds, unplanned capex and reputational risk. In parallel, the overload of the QA team threatened to tip into the departure of further key staff, in a swept-clean market where the German pharmaceutical industry is short of roughly 176,000 skilled workers and about one in four positions in production remains vacant.

The visible market produced no suitable profiles. That is no coincidence. QP-qualified QM leaders with robust sterile experience are the rarest intersection of an already scarce pharma talent market, where among pharmacists a vacancy-surplus ratio of around 70 percent was recently measured. This position could not be filled through job boards or actively searching candidates.

As a CDMO executive search firm, ANDRIS Consulting therefore deliberately relied on direct search and the activation of passive candidates through its personal network. The search radius was widened through transfer thinking, away from the narrow competitive field and towards structurally identical sterile contract manufacturing. In the aptitude diagnostics we examined not only the technical depth in aseptic process management, CCS logic under Annex 1 and computer system validation, but specifically resilience under audit pressure and the cultural fit with an owner-led mid-sized business. We were looking for a personality who leads a live audit not as a state of emergency but as a controllable part of normal operations.